

DJ-1 and α SYN in LRRK2 CSF do not correlate with striatal dopaminergic function

Min Shi^{a,1}, Amy R. Furay^{a,1}, Vesna Sossi^b, Jan O. Aasly^c, Jeff Armaly^a, Yu Wang^{a,d},
Zbigniew K. Wszolek^e, Ryan J. Uitti^e, Kazuko Hasegawa^f, Teruo Yokoyama^f,
Cyrus P. Zabetian^{g,h,i}, James B. Leverenz^{h,i,j,k}, A. Jon Stoessl^l, Jing Zhang^{a,*}

^a Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA

^b Department of Physics and Astronomy, University of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, BC, Canada

^c Department of Neurology, St. Olavs Hospital, Trondheim, Norway

^d Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

^e Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, USA

^f Department of Neurology, National Hospital Organization, Sagami National Hospital, Kanagawa, Japan

^g Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA

^h Parkinson's Disease Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA

ⁱ Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA

^j Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA

^k Mental Illness Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA

^l Pacific Parkinson's Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada

Received 28 March 2011; received in revised form 15 July 2011; accepted 10 September 2011

Abstract

Previous studies demonstrated decreased levels of DJ-1 and α -synuclein (α SYN) in human cerebrospinal fluid (CSF) in patients with Parkinson's disease (PD), but neither marker correlated with PD severity, raising the possibility that they may be excellent progression markers during early or preclinical phases of PD. Individuals carrying the leucine-rich repeat kinase 2 (LRRK2) gene mutation are at increased risk for PD, and the phenotype of LRRK2 patients is almost identical to sporadic PD. To determine whether dopaminergic dysfunction in the basal ganglia, as determined by positron emission tomography (PET) scans, correlates with CSF levels of DJ-1 and α SYN during preclinical stages, Luminex assays were used to analyze CSF samples from asymptomatic LRRK2 mutation carriers, along with carriers who presented with a clinical diagnosis of PD. The data revealed no statistically significant relationship between PET scan evidence of loss of striatal dopaminergic function and the CSF biomarkers DJ-1 and α SYN, except for a weak correlation between DJ-1 and methylphenidate binding, suggesting that the use of these potential biomarkers on their own to screen LRRK2 gene mutation carriers for PD is not appropriate.

© 2012 Elsevier Inc. All rights reserved.

Keywords: Parkinson's disease; LRRK2; Gene mutation; Biomarker; DJ-1; α -synuclein

1. Introduction

A majority of dopaminergic cell bodies in the substantia nigra are lost before clinical symptoms of Parkinson's disease (PD) are evident, so there is an urgent need for pre-clinical biomarkers that correlate with dopaminergic cell loss and other PD pathology. Previously, we and others

* Corresponding author at: Department of Pathology, University of Washington School of Medicine, HMC Box 359635, 325 9th Avenue, Seattle, WA 98104, USA. Tel.: +1 206 897 5245; fax: +1 206 897 5452.

E-mail address: zhangj@uw.edu (J. Zhang).

¹ The authors have contributed equally.

reported decreased levels of DJ-1 and α -synuclein (α SYN) in human cerebrospinal fluid (CSF) in several large cohorts of PD patients. However, there was no statistically significant relationship between biomarker levels and PD severity in sporadic PD patients (Hong et al., 2010), suggesting that there might be a “floor” effect and these biomarkers may alter more significantly during early stages of the disease, i.e., correlate with early PD progression. Developing biomarkers that predict early phase disease onset and progression may help in the development of treatments designed to slow disease progression and enable treatment when the disease is most responsive to therapy. Because carriers of a mutated gene encoding leucine-rich repeat kinase 2 (LRRK2) are at increased risk for PD (Adams et al., 2005; Cookson, 2010), they are an ideal population for studying disease onset and progression.

2. Methods

Symptomatic ($n = 8$) or asymptomatic ($n = 18$) individuals from Japan, the United States, and Norway carrying the LRRK2 mutated gene were included in this study; all had standard informed consent, clinical examination, and tests. Subjects were positron emission tomography (PET) scanned with 3 different radiolabeled tracers (^{18}F -6-fluoro-L-dopa [FDOPA], ^{11}C -(\pm)- α -dihydrotetrabenazine [DTBZ], and ^{11}C -d-threo-methylphenidate [MP]) to determine the uptake and decarboxylation of levodopa in the striatum, as well as vesicular monoamine and plasmalemmal dopamine transporter binding. CSF samples were collected via lumbar puncture; Luminex assays measuring α SYN and DJ-1 were used to analyze biomarkers. Statistical analysis was performed using PASW 18.9 Statistics software (SPSS, Inc., Chicago, IL, USA). Correlation between CSF α SYN and DJ-1 levels and PET measurements was evaluated using Kendall's rank correlation coefficient; overall group differences in CSF biomarkers were analyzed using Mann-Whitney Wilcoxon rank sum tests. For more detail, see the Supplementary Methods section.

3. Core data/results

Consistent with previous studies, abnormal (decreased) PET changes were observed in asymptomatic and symptomatic subjects (Adams et al., 2005). Because previous reports suggest that blood contamination of CSF (indexed by CSF hemoglobin levels) affects α SYN and DJ-1 levels (Hong et al., 2010), 3 subjects (2 with PD, 1 asymptomatic) with hemoglobin levels > 250 ng/mL were eliminated from further analysis. As graphically represented in Supplementary Fig. 1 (DJ-1 only) and summarized in Supplementary Tables 1 and 2 (DJ-1 and α SYN), there was a slight trend toward a positive correlation between CSF DJ-1 and PET measurements, particularly DTBZ and MP. Next, to determine if such a relationship existed in carriers of the G2019S mutation, the most common form of LRRK2 genetic mutation, we analyzed only G2019S mutation carriers (3 with

PD, 8 asymptomatic) but found no relationship between PET scan results and CSF biomarkers, except for a weak correlation between DJ-1 and MP. Consistent with our previous study in sporadic PD patients (Hong et al., 2010), there was no significant correlation between DJ-1 or α SYN levels in CSF and PD severity (Unified Parkinson's Disease Rating Scale motor scores and Hoehn and Yahr stage); there were also no differences between groups in either potential biomarker, probably due to limited case numbers (see Supplementary data section).

4. Discussion

The purpose of this study was to determine if CSF levels of α SYN and DJ-1 are suitable preclinical biomarkers for detecting early phase PD by correlating them with PET scan data measuring progressive loss of striatal dopaminergic function in primarily asymptomatic LRRK2 mutation carriers. These data indicate that CSF α SYN and DJ-1 are not significantly correlated with dopamine dysfunction/cell loss in all LRRK2 gene mutation carriers combined and only a weak correlation was found in the G2019S subset of carriers alone. Although previous studies have suggested that the total levels of α SYN and DJ-1 in CSF are potential diagnostic biomarkers for sporadic PD, with relatively high sensitivity and specificity (Hong et al., 2010), the results of the present study suggest that on their own, they may not be appropriate biomarkers for preclinical or early phase PD diagnosis and/or disease progression, at least in the population of LRRK2 gene mutation carriers, which might be different from typical sporadic PD patients. Although the sample size is small, the present data set strongly suggest that efforts should be directed toward identifying other potential biomarkers, including specific α SYN and DJ-1 species/isoforms, with more robust predictive validity.

Disclosure statement

The authors report no actual or potential conflict of interest.

This study was approved by the Institutional Review Boards of all participating institutions, and all participants provided informed consent.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.neurobiolaging.2011.09.015](https://doi.org/10.1016/j.neurobiolaging.2011.09.015).

References

- Adams, J.R., van Netten, H., Schulzer, M., Mak, E., McKenzie, J., Strongosky, A., Sossi, V., Ruth, T.J., Lee, C.S., Farrer, M., Gasser,

- T., Uitti, R.J., Calne, D.B., Wszolek, Z.K., Stoessl, A.J., 2005. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain* 128, 2777–2785.
- Cookson, M.R., 2010. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat. Rev. Neurosci.* 11, 791–797.
- Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., Jankovic, J., Zabetian, C.P., Leverenz, J.B., Baird, G., Montine, T.J., Hancock, A.M., Hwang, H., Pan, C., Bradner, J., Kang, U.J., Jensen, P.H., Zhang, J., 2010. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain* 133:713–726.